Abstract:Abstract Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative proposes therapeutic targets for inflammatory bowel disease (IBD) to be used for a treat-to-target clinical management strategy. However, there is lack of information regarding how many patients actually achieve defined treatment targets as outlined in STRIDE-II after initiation of new therapies. The objective of this study was to investigate the treatment response of Crohn’s disease (CD) patients according to the STRIDE-II recommendations in the first year after starting a new pharmacological therapy in clinical practice. Methods CD patients included in a remote monitoring care-path using myIBDcoach, starting a new therapy between January 1st 2020 and December 31st 2021 were eligible for inclusion. The short-term (2-4 months) treatment target was defined as clinical response based on at least 50% decrease in the Monitor IBD at home (MIAH) questionnaire, a patient-reported outcome measure validated to predict endoscopic disease activity. Intermediate (5-9 months) targets were clinical remission (MIAH ≤3.6) and normalization of inflammatory parameters, i.e. faecal calprotectin (<150 ug/g) and C-reactive protein ([CRP] <10 mg/L). Long-term (10-12 months) targets were absence of disability (IBD-control questionnaire ≥13), and a combination of MIAH score ≤3.6 and calprotectin <150 ug/g as surrogate markers for endoscopic remission. Results 39 CD patients were included in the current analysis, of which two started treatment with thiopurines and 37 with a biological. At baseline, median MIAH score was 3.0 (IQR 3.1) and median IBD-control score was 8.5 (IQR 9.0). After three months of therapy, 26% of patients showed clinical response and 64% of patients were in clinical remission (median MIAH 2.2 [IQR 1.8]). As for intermediate targets, clinical remission was seen in 62% (median MIAH 2.0 [IQR 2.3]), and CRP and calprotectin normalization in 79% and 59% of patients, respectively. At the end of follow-up, 41% had low surrogate marker scores indicative for endoscopic remission (median MIAH 1.9 [IQR 1.6] and median calprotectin 109.0 [IQR 241.0]). Resolution of disability was achieved in 65% (median IBD-control score 14.0 [IQR 6.0]). Three patients (9%) achieved all treatment targets within a year of follow-up (Table 1). Conclusion This study used an incident user real-world cohort to evaluate the STRIDE-II recommendations. While all patients achieved at least one treatment target, only 9% achieved all treatment targets according to the STRIDE-II recommendations. Using these recommendations provides good guidance in clinical settings. However, treatment approaches need to be improved to reach the optimal outcomes in daily clinical practice.

Treatment goals for inflammatory bowel disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Treatment of Inflammatory Bowel Disease: A Comprehensive Review

Recent Advances in the Treatment of IBD: Targets, Mechanisms and Related Therapies.

Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

Recent progress in treatment of inflammatory bowel disease

The Future of IBD Therapy: Where Are We and Where Should We Go Next?

Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics

Emerging pharmacotherapy for inflammatory bowel diseases.

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Treat to target in Crohn’s disease: A practical guide for clinicians

New concepts on treatment of inflammatory bowel disease

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease

Standardized treatment for inflammatory bowel disease

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease

Current and emerging therapeutic targets for IBD

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

P344 Achieving Crohn's Disease treatment targets following the STRIDE-II recommendations in clinical practice